KaydedilenlerDerginizi ekleyin

Dergiler / Retina-Vitreus / 2022 / Cilt: 31 - Sayı: 3

Bilateral Uveitis and Papillitis During Metastatic Melanoma Treatment with Dabrafenib and Trametinib

Mehmet Serdar DERVİŞOĞULLARI
Sayfa
275–277
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Patients should be informed for the need of consecutive eye examinations.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: To report a patient who developed bilateral uveitis and papillitis during dabrafenib and trametinib treatment for metastatic cutaneous melanoma.
📊
Temel Bulgular & Veri:Results: A patient under treatment for metastatic cutaneous melanoma with dabrafenib and trametinib presented to our clinic with 1 month of bilateral visual blurring complaint.
💡
Sonuç & Katkı:Patients should be informed for the need of consecutive eye examinations.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: To report a patient who developed bilateral uveitis and papillitis during dabrafenib and trametinib treatment for metastatic cutaneous melanoma. Material and Methods: Retrospective chart review. Results: A patient under treatment for metastatic cutaneous melanoma with dabrafenib and trametinib presented to our clinic with 1 month of bilateral visual blurring complaint. At ophthalmological examination, bilateral uveitis and papillitis were observed. After stopping dabrafenib and trametinib and initiating topical steroid administration, intraocular inflammation and papillitis improved in 2 months. Final visual acuities were 20/20 in both eyes. Conclusion: Mitogen activated protein kinase (MAPK) inhibitors Dabrafenib anf trametinib can lead to ocular toxicity. Patients should be informed for the need of consecutive eye examinations.

🔖

Bu Makaleye Atıf Yap

DERVİŞOĞULLARI, M. S. (2022). Bilateral Uveitis and Papillitis During Metastatic Melanoma Treatment with Dabrafenib and Trametinib. Retina-Vitreus, Cilt: 31 - Sayı: 3, 275–277. https://ajindex.com/articles/589007

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012;6:391-405
  2. Moorthy RS, Moorthy MS, Cunningham ET Jr. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29:588-603
  3. Woltsche N, Kruger MA, Weger M, Wolf IH, Seidel G. Intravitreal steroid treatment for uveitis associated with Dabrafenib and Trametinib for metastatic cutaneous melanoma. Ocular Immunol Inflamm 2020; 6;1-3
  4. Naranjo CA, Busto U, Sellers EM, Sandor P, Rui I, Roberts EA, Janecek E, DomecqC, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45 5. Guedj M, Queant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, Longvert C, Gantzer A, Brezin A. Uveitis in patients with late stage cuyaneous melanoma treated with Vemurafenib. JAMA Ophthalmol 2014;132:1421-25
  5. Dy GK, Adjei AA. Understanding, recognizing and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63:247-79
  6. Joshi L, Karydis A, Gmenetzi M, Shao EH, Taylor SR. Uveitis as a result of MAP Kinase pathway inhibition. Case Rep Ophthalmol. 2013;4:279-82
  7. Mc Cannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014;132:1005-9
  8. Mozo Cuadrado M, Tabuenca Del Barrio L, Compains Silva E. Bilateral Drug-Induced Uveitis and Epiretinal Membrane during the Treatment of a Metastatic Cutaneous Melanoma. Ocul Immunol Inflamm. 2019 Nov 22:1-3
  9. Huang W, Yang AH, Matsumoto D, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther. 2009;25:519-30
  10. Lim J, Lomax AJ, McNeil C, Harrisber B. Uveitis and papillitis in the setting of Dabrafenib and Trametinib therapy for metastatic melanoma:a case report. Ocul Immunol Inflamm. 2018;26:628- 31.